Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?
Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatme...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/19/4960 |
| _version_ | 1797480049070309376 |
|---|---|
| author | Daniel Ruiz-Molina Xiaoman Mao Paula Alfonso-Triguero Julia Lorenzo Jordi Bruna Victor J. Yuste Ana Paula Candiota Fernando Novio |
| author_facet | Daniel Ruiz-Molina Xiaoman Mao Paula Alfonso-Triguero Julia Lorenzo Jordi Bruna Victor J. Yuste Ana Paula Candiota Fernando Novio |
| author_sort | Daniel Ruiz-Molina |
| collection | DOAJ |
| description | Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatments do not much improve the overall survival of GB patients, which is still below two years (the 5-year survival rate is below 7%). Despite various approaches having been followed to increase the release of anticancer drugs into the brain, few of them demonstrated a significant success, as the blood brain barrier (BBB) still restricts its uptake, thus limiting the therapeutic options. Therefore, enormous efforts are being devoted to the development of novel nanomedicines with the ability to cross the BBB and specifically target the cancer cells. In this context, the use of nanoparticles represents a promising non-invasive route, allowing to evade BBB and reducing systemic concentration of drugs and, hence, side effects. In this review, we revise with a critical view the different families of nanoparticles and approaches followed so far with this aim. |
| first_indexed | 2024-03-09T21:54:33Z |
| format | Article |
| id | doaj.art-2faf68dbdac34198a8c7fc3a76d8b03c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T21:54:33Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-2faf68dbdac34198a8c7fc3a76d8b03c2023-11-23T19:59:32ZengMDPI AGCancers2072-66942022-10-011419496010.3390/cancers14194960Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?Daniel Ruiz-Molina0Xiaoman Mao1Paula Alfonso-Triguero2Julia Lorenzo3Jordi Bruna4Victor J. Yuste5Ana Paula Candiota6Fernando Novio7Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, SpainCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, SpainCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, SpainInstitut de Biotecnologia i de Biomedicina, Departament de Bioquimica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, SpainNeuro-Oncology Unit, Bellvitge University Hospital-ICO (IDIBELL), Avinguda de la Gran Via de l’Hospitalet, 199-203, L’Hospitalet de Llobregat, 08908 Barcelona, SpainInstituto de Neurociencias. Universitat Autònoma de Barcelona (UAB), Campus UAB, 08193 Cerdanyola del Vallès, SpainInstitut de Biotecnologia i de Biomedicina, Departament de Bioquimica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, SpainCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, SpainGlioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatments do not much improve the overall survival of GB patients, which is still below two years (the 5-year survival rate is below 7%). Despite various approaches having been followed to increase the release of anticancer drugs into the brain, few of them demonstrated a significant success, as the blood brain barrier (BBB) still restricts its uptake, thus limiting the therapeutic options. Therefore, enormous efforts are being devoted to the development of novel nanomedicines with the ability to cross the BBB and specifically target the cancer cells. In this context, the use of nanoparticles represents a promising non-invasive route, allowing to evade BBB and reducing systemic concentration of drugs and, hence, side effects. In this review, we revise with a critical view the different families of nanoparticles and approaches followed so far with this aim.https://www.mdpi.com/2072-6694/14/19/4960glioblastomapreclinical modelnanoparticlesdrug deliverybrain cancerBBB |
| spellingShingle | Daniel Ruiz-Molina Xiaoman Mao Paula Alfonso-Triguero Julia Lorenzo Jordi Bruna Victor J. Yuste Ana Paula Candiota Fernando Novio Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help? Cancers glioblastoma preclinical model nanoparticles drug delivery brain cancer BBB |
| title | Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help? |
| title_full | Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help? |
| title_fullStr | Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help? |
| title_full_unstemmed | Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help? |
| title_short | Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help? |
| title_sort | advances in preclinical clinical glioblastoma treatment can nanoparticles be of help |
| topic | glioblastoma preclinical model nanoparticles drug delivery brain cancer BBB |
| url | https://www.mdpi.com/2072-6694/14/19/4960 |
| work_keys_str_mv | AT danielruizmolina advancesinpreclinicalclinicalglioblastomatreatmentcannanoparticlesbeofhelp AT xiaomanmao advancesinpreclinicalclinicalglioblastomatreatmentcannanoparticlesbeofhelp AT paulaalfonsotriguero advancesinpreclinicalclinicalglioblastomatreatmentcannanoparticlesbeofhelp AT julialorenzo advancesinpreclinicalclinicalglioblastomatreatmentcannanoparticlesbeofhelp AT jordibruna advancesinpreclinicalclinicalglioblastomatreatmentcannanoparticlesbeofhelp AT victorjyuste advancesinpreclinicalclinicalglioblastomatreatmentcannanoparticlesbeofhelp AT anapaulacandiota advancesinpreclinicalclinicalglioblastomatreatmentcannanoparticlesbeofhelp AT fernandonovio advancesinpreclinicalclinicalglioblastomatreatmentcannanoparticlesbeofhelp |